[Click eStock] "WSI, Highlighting Growth Potential of Medical AI Robots and Subsidiaries"

On the 25th, Growth Research stated that the growth potential of medical AI robot development and pharmaceutical manufacturing subsidiary Introbiopharma will be highlighted for WSI. No investment opinion or target price was provided.

Researcher Lee Jaemo of Growth Research said, "The pharmaceutical and medical device distribution business has been stably operated, recording sales of 40.4 billion KRW last year, a 30.9% increase compared to the previous year," adding, "Along with the continuous growth of existing businesses, growth of subsidiaries Introbiopharma and EasyMedibot is expected."

Lee explained, "EasyMedibot, a subsidiary, developed the laparoscopic surgery robot 'U-BOT,' which addresses medical workforce shortages and improves inefficient surgical environments," and added, "It is the first domestically developed uterine elevator that does not require a surgical assistant, enabling intuitive and safe operation."

He continued, "Through the acquisition of Introbiopharma, the pharmaceutical manufacturing business is also expanding," and added, "Synergy effects are expected between Introbiopharma's research and development (R&D) capabilities and WSI's nationwide distribution network of over 400 locations."